aid: endo-international
url: https://raw.githubusercontent.com/api-evangelist/endo-international/refs/heads/main/apis.yml
name: Endo International
type: Index
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/apis-json-logo.jpg
tags:
  - Pharmaceuticals
  - Specialty Pharma
  - Generics
  - Sterile Injectables
  - Urology
  - Orthopedics
  - Chapter 11
  - Opioid Settlement
description: >-
  Endo International was a specialty pharmaceutical company best known for
  Xiaflex (collagenase clostridium histolyticum), branded urology and
  orthopedic products, and a large sterile-injectables and generics business
  (Par Pharmaceutical). Endo filed Chapter 11 in August 2022 amid mass opioid
  litigation tied to its legacy Opana ER franchise, and emerged in April 2024
  as the private company Endo, Inc., owned by its former creditors. On
  July 31, 2025, Endo combined with Mallinckrodt; the merged group then
  separated in November 2025 into two independent companies — Keenova
  Therapeutics (specialty branded therapeutics, including the former Endo
  Xiaflex/urology/orthopedics portfolio and Mallinckrodt specialty brands)
  and Par Health (generics, sterile injectables, and pharmaceutical Active
  Pharmaceutical Ingredients manufacturing). Endo no longer operates as a
  standalone public-facing pharmaceutical company. There is no public
  developer program, OpenAPI specification, SDK, or technology API surface
  associated with Endo, the post-emergence Endo Inc, Keenova Therapeutics,
  or Par Health. Any references to "API" on the successor companies' sites
  refer to pharmaceutical Active Pharmaceutical Ingredients, not software
  application programming interfaces.
created: '2026-05-23'
modified: '2026-05-23'
specificationVersion: '0.19'
apis: []
common:
  - type: DomainSecurity
    url: security/endo-international-domain-security.yml
  - type: Website
    url: https://www.endo.com
  - type: SuccessorWebsite
    url: https://www.keenova.com
  - type: SuccessorWebsite
    url: https://www.parhealth.com
  - type: MergerPartnerWebsite
    url: https://www.mallinckrodt.com
  - type: ChapterEleven
    url: https://restructuring.ra.kroll.com/endo
  - type: OpioidSettlement
    url: https://nationalopioidsettlement.com
  - type: LinkedIn
    url: https://www.linkedin.com/company/endo-international
  - type: SECFilings
    url: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001593034
overlays:
  - type: APIEvangelistRanking
    url: corporate-event-only
events:
  - type: ChapterEleven
    date: '2022-08-16'
    description: >-
      Endo International plc and certain subsidiaries filed voluntary petitions
      for Chapter 11 in the US Bankruptcy Court for the Southern District of
      New York, citing opioid-related litigation and balance-sheet pressure.
  - type: Emergence
    date: '2024-04-23'
    description: >-
      Endo emerged from Chapter 11 as Endo, Inc., a privately held company
      owned by its former creditors, with reduced debt and funded opioid
      settlement obligations.
  - type: Merger
    date: '2025-07-31'
    description: >-
      Endo combined with Mallinckrodt to form a single specialty
      pharmaceuticals and generics group.
  - type: Separation
    date: '2025-11'
    description: >-
      The combined company separated into Keenova Therapeutics
      (specialty branded) and Par Health (generics, sterile injectables,
      pharmaceutical APIs).
maintainers:
  - FN: Kin Lane
    email: kin@apievangelist.com